Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2023-09-19 00:00:00 ET · period of report 2023-09-15 · accession 0001209191-23-050072 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-19 | 2023-09-15 | ACAD | Kihara James | Principal Accounting Off | S - Sale | $25.88 | -2,000 | 10.8K | -16% | -$51.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-15 | S | D | 2,000 | $25.88 | 10,778 | D | — | — | (F3) Includes 23 shares purchased by the Reporting Person in open market transaction on November 21, 2020, with a purchase price of $43.01 per share. (F2) Includes an aggregate of 3,611 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on November 13, 2020, May 14, 2021, November 15, 2021, May 13, 2022, November 15, 2022 and May 15, 2023. |